Novartis Kisqali Cuts Death Risk 19% After Six Years, Data Shows
Trial data presented at the European Society for Medical Oncology congress in Madrid show Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.